Multiple System Atrophy Msa Epidemiology Forecast

DelveInsight’s ‘Multiple System Atrophy (MSA)-Epidemiology Forecast–2030’ report delivers an in-depth understanding of the MSA, historical and forecasted epidemiology as well as the MSA trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030


Multiple System Atrophy (MSA) Disease Understanding

Multiple System Atrophy (MSA), formerly known as Shy-Drager Syndrome, is a rare, degenerative neurological disorder affecting the body's involuntary (autonomic) functions, including blood pressure, breathing, bladder function, and motor control. The term multiple system atrophy was first introduced in the medical literature in 1969. It encompasses three presentations of a single disease formerly thought to be separate disorders, specifically Shy-Drager syndrome (which emphasized autonomic dysfunction), striatonigral degeneration (which emphasized parkinsonian symptoms), and sporadic olivopontocerebellar atrophy (which emphasized cerebellar symptoms).


MSA is broken down into two main subtypes based on the predominant symptom: MSA-predominant Parkinsonism (MSA-P) and MSA-predominant cerebellar ataxia (MSA-C). A patient diagnosed with MSA-P may over time appear to have MSA-C and vice versa, so these categorizations are not always set in stone.


Multiple System Atrophy (MSA) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of MSA, Diagnosed Prevalent Patient Population of MSA, Gender-specific Diagnosed Prevalent Population of MSA, Age-specific Diagnosed Prevalent Population of MSA, and Type-specific Diagnosed Prevalent Population of MSA scenario of MSA in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.


Multiple System Atrophy (MSA) Detailed Epidemiology Segmentation

  • In 2017, the prevalent cases of MSA in the 7MM was 41,033.
  • The diagnosed patient pool in the 7MM comprised of 22,568 patients in 2017.
  • In the case of the United States, the prevalent population of MSA was 14,496 in 2017.
  • It has been observed that males accounted for more prevalent cases of MSA than females. In 2017, out of the total diagnosed prevalent cases of MSA, 4,784 cases accounted for males and 3,189 for females, in the US.
  • In the epidemiology model of MSA, for age-specific cases, the categorization is done in the following age group, i.e., 30–39 Years, 40–49 Years, 50–59 Years, 60–79 Years, and 80+ Years. In the US, the majority of the cases are observed in the age group, 50–59 Years (51.52%), whereas, in EU-5, and Japan, the majority of the cases are observed in the age group 60–79 Years.
  • MSA is broken down into two main subtypes based on the predominant symptom: MSA-predominant Parkinsonism (MSA-P), and MSA-predominant cerebellar ataxia (MSA-C).
  • In the US and EU-5 countries, MSA-P type is more prevalent as compared to MSA-C type, but in Japan, the trend is the opposite. In Japan, MSA-C type (70%) is more prevalent as compared to MSA-P (30%). 
  • In the EU5, the highest prevalent cases were reported to be in Italy followed by Germany, and the United Kingdom whereas the lowest prevalence rates were reported in Spain during the period of 2017–2030.
  • Japan was reported to have 10,360 prevalent cases of MSA in 2017.


Scope of the Report

  • The report covers the descriptive overview of MSA, explaining its signs and symptoms, and pathophysiology.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of MSA.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of MSA, Diagnosed Prevalent Patient Population of MSA, Gender-specific Diagnosed Prevalent Population of MSA, Age-specific Diagnosed Prevalent Population of MSA, and Type-specific Diagnosed Prevalent Population of MSA.


Report Highlights

  • 11-Year Forecast of MSA
  • 7MM Coverage
  • Total Prevalent Cases of MSA
  • Diagnosed Prevalent Patient Population of MSA
  • Gender-specific Diagnosed Prevalent Population of MSA
  • Age-specific Diagnosed Prevalent Population of MSA
  • Type-specific Diagnosed Prevalent Population of MSA


Key Questions Answered

  • What are the disease risk, burdens, and unmet needs of MSA?
  • What is the historical MSA patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of MSA at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to MSA?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of MSA during the forecast period (2020–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?


Reasons to buy

The MSA report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM MSA epidemiology forecast.
  • The MSA epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The MSA epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population


1. Key Insights

2. Executive Summary of Multiple System Atrophy (MSA)

3. Multiple System Atrophy (MSA) Epidemiology Overview at a Glance

3.1. Epidemiological Share (%) Distribution of Multiple System Atrophy in 2017

3.2. Epidemiological Share (%) Distribution of Multiple System Atrophy in 2030

4. Disease Background and Overview: Multiple System Atrophy (MSA)

4.1. Introduction

4.2. Subtypes of MSA

4.2.1. Parkinsonian MSA (MSA-P)

4.2.2. Cerebral MSA (MSA-C)

4.3. Signs or symptoms

4.3.1. Common and distinguishing features of MSA

4.4. Cellular Neuropathology

4.5. Working Hypothesis for the Pathogenesis of MSA

4.6. Biomarkers

4.7. Diagnosis

4.8. Diagnosis Guidelines

5. Epidemiology and Patient Population

5.1. Key Findings

5.2. Epidemiology Methodology

5.3. 7MM Total Prevalent Population of MSA

5.4. 7MM Total Diagnosed Prevalence of MSA

6. Country Wise-Epidemiology of MSA

6.1. United States

6.1.1. Assumptions and Rationale

6.1.2. Total Prevalent Cases of MSA in the United States

6.1.3. Total Diagnosed Prevalent Cases of MSA in the United States

6.1.4. Gender-specific Diagnosed Prevalent Cases of MSA in the United States

6.1.5. Age-specific Diagnosed Prevalent Cases of MSA in the United States

6.1.6. Type-specific Diagnosed Prevalent Cases of MSA in the United States

6.2. EU-5 Countries

6.2.1. Assumptions and Rationale

6.2.2. Germany

6.2.2.1. Total Prevalent Cases of MSA in Germany

6.2.2.2. Total Diagnosed Prevalent Cases of MSA in Germany

6.2.2.3. Gender-specific Diagnosed Prevalent Cases of MSA in Germany

6.2.2.4. Age-specific Diagnosed Prevalent Cases of MSA in Germany

6.2.2.5. Type-specific Diagnosed Prevalent Cases of MSA in Germany

6.2.3. France

6.2.3.1. Total Prevalent Cases of MSA in France

6.2.3.2. Total Diagnosed Prevalent Cases of MSA in France

6.2.3.3. Gender-specific Diagnosed Prevalent Cases of MSA in France

6.2.3.4. Age-specific Diagnosed Prevalent Cases of MSA in France

6.2.3.5. Type-specific Diagnosed Prevalent Cases of MSA in France

6.2.4. Italy

6.2.4.1. Total Prevalent Cases of MSA in Italy

6.2.4.2. Total Diagnosed Prevalent Cases of MSA in Italy

6.2.4.3. Gender-specific Diagnosed Prevalent Cases of MSA in Italy

6.2.4.4. Age-specific Diagnosed Prevalent Cases of MSA in Italy

6.2.4.5. Type-specific Diagnosed Prevalent Cases of MSA in Italy

6.2.5. Spain

6.2.5.1. Total Prevalent Cases of MSA in Spain

6.2.5.2. Total Diagnosed Prevalent Cases of MSA in Spain

6.2.5.3. Gender-specific Diagnosed Prevalent Cases of MSA in Spain

6.2.5.4. Age-specific Diagnosed Prevalent Cases of MSA in Spain

6.2.5.5. Type-specific Diagnosed Prevalent Cases of MSA in Spain

6.2.6. United Kingdom

6.2.6.1. Total Prevalent Cases of MSA in the UK

6.2.6.2. Total Diagnosed Prevalent Cases of MSA in the UK

6.2.6.3. Gender-specific Diagnosed Prevalent Cases of MSA in the UK

6.2.6.4. Age-specific Diagnosed Prevalent Cases of MSA in the UK

6.2.6.5. Type-specific Diagnosed Prevalent Cases of MSA in the UK

6.3. Japan

6.3.1. Assumptions and Rationale

6.3.2. Total Prevalent Cases of MSA in Japan

6.3.3. Total Diagnosed Prevalent Cases of MSA in Japan

6.3.4. Gender-specific Diagnosed Prevalent Cases of MSA in Japan

6.3.5. Age-specific Diagnosed Prevalent Cases of MSA in Japan

6.3.6. Type-specific Diagnosed Prevalent Cases of MSA in Japan

7. Appendix

7.1. Bibliography

7.2. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

List of Table

Table 1 Summary of Multiple System Atrophy (MSA), Epidemiology, and Key Events (2017–2030)

Table 2 Criteria for possible MSA

Table 3 Additional features of possible MSA

Table 4 Criteria for the diagnosis of probable MSA

Table 5 Features supporting (red flags) and not supporting a diagnosis of MSA

Table 6 Total Prevalence of MSA in the 7MM (2017-2030)

Table 7 Total Diagnosed Prevalence of MSA in the 7MM (2017-2030)

Table 8 Total Prevalent Cases of MSA in the United States (2017–2030)

Table 9 Total Diagnosed Prevalent Cases of MSA in the United States (2017–2030)

Table 10 Gender-specific Diagnosed Prevalent Cases of MSA in the United States (2017–2030)

Table 11 Age-specific Diagnosed Prevalent Cases of MSA in the United States (2017–2030)

Table 12 Type-specific Diagnosed Prevalent Cases of MSA in the United States (2017–2030)

Table 13 Total Prevalent Cases of MSA in Germany (2017–2030)

Table 14 Total Diagnosed Prevalent Cases of MSA in Germany (2017–2030)

Table 15 Gender-specific Diagnosed Prevalent Cases of MSA in Germany (2017–2030)

Table 16 Age-specific Diagnosed Prevalent Cases of MSA in Germany (2017–2030)

Table 17 Type-specific Diagnosed Prevalent Cases of MSA in Germany (2017–2030)

Table 18 Total Prevalent Cases of MSA in France (2017–2030)

Table 19 Total Diagnosed Prevalent Cases of MSA in France (2017–2030)

Table 20 Gender-specific Diagnosed Prevalent Cases of MSA in France (2017–2030)

Table 21 Age-specific Diagnosed Prevalent Cases of MSA in France (2017–2030)

Table 22 Type-specific Diagnosed Prevalent Cases of MSA in France (2017–2030)

Table 23 Total Prevalent Cases of MSA in Italy (2017–2030)

Table 24 Total Diagnosed Prevalent Cases of MSA in Italy (2017–2030)

Table 25 Gender-specific Diagnosed Prevalent Cases of MSA in Italy (2017–2030)

Table 26 Age-specific Diagnosed Prevalent Cases of MSA in Italy (2017–2030)

Table 27 Type-specific Diagnosed Prevalent Cases of MSA in Italy (2017–2030)

Table 28 Total Prevalent Cases of MSA in Spain (2017–2030)

Table 29 Total Diagnosed Prevalent Cases of MSA in Spain (2017–2030)

Table 30 Gender-specific Diagnosed Prevalent Cases of MSA in Spain (2017–2030)

Table 31 Age-specific Diagnosed Prevalent Cases of MSA in Spain (2017–2030)

Table 32 Type-specific Diagnosed Prevalent Cases of MSA in Spain (2017–2030)

Table 33 Total Prevalent Cases of MSA in the UK (2017–2030)

Table 34 Total Diagnosed Prevalent Cases of MSA in the UK (2017–2030)

Table 35 Gender-specific Diagnosed Prevalent Cases of MSA in the UK (2017–2030)

Table 36 Age-specific Diagnosed Prevalent Cases of MSA in the UK (2017–2030)

Table 37 Type-specific Diagnosed Prevalent Cases of MSA in the UK (2017–2030)

Table 38 Total Prevalent Cases of MSA in Japan (2017–2030)

Table 39 Total Diagnosed Prevalent Cases of MSA in Japan (2017–2030)

Table 40 Gender-specific Diagnosed Prevalent Cases of MSA in Japan (2017–2030)

Table 41 Age-specific Diagnosed Prevalent Cases of MSA in Japan (2017–2030)

Table 42 Type-specific Diagnosed Prevalent Cases of MSA in Japan (2017–2030)

List of Figures

Figure 1 Causes of Multiple System Atrophy (MSA)

Figure 2 Subtype of MSA

Figure 3 Locating the Cerebellum and Basal Ganglia

Figure 4 Symptoms of MSA

Figure 5 Possible pathological α-Syn-spreading and accumulation mechanism leading to neurodegeneration

Figure 6 Current and future diagnostic biomarkers of MSA

Figure 7 Diagnosis of MSA

Figure 8 Diagnostic scheme for MSA according to the current consensus diagnostic criteria

Figure 9 Limitations of clinical diagnosis based on clinical signs and symptoms

Figure 10 Related Disorders

Figure 11 Total Prevalence of MSA in the 7MM (2017-2030)

Figure 12 Total Diagnosed Prevalence of MSA in the 7MM (2017-2030)

Figure 13 Total Prevalent Cases of MSA in the United States (2017–2030)

Figure 14 Total Diagnosed Prevalent Cases of MSA in the United States (2017–2030)

Figure 15 Gender-specific Diagnosed Prevalent Cases of MSA in the United States (2017–2030)

Figure 16 Age-specific Diagnosed Prevalent Cases of MSA in the United States (2017–2030)

Figure 17 Type-specific Diagnosed Prevalent Cases of MSA in the United States (2017–2030)

Figure 18 Total Prevalent Cases of MSA in Germany (2017–2030)

Figure 19 Total Diagnosed Prevalent Cases of MSA in Germany (2017–2030)

Figure 20 Gender-specific Diagnosed Prevalent Cases of MSA in Germany (2017–2030)

Figure 21 Age-specific Diagnosed Prevalent Cases of MSA in Germany (2017–2030)

Figure 22 Type-specific Diagnosed Prevalent Cases of MSA in Germany (2017–2030)

Figure 23 Total Prevalent Cases of MSA in France (2017–2030)

Figure 24 Total Diagnosed Prevalent Cases of MSA in France (2017–2030)

Figure 25 Gender-specific Diagnosed Prevalent Cases of MSA in France (2017–2030)

Figure 26 Age-specific Diagnosed Prevalent Cases of MSA in France (2017–2030)

Figure 27 Type-specific Diagnosed Prevalent Cases of MSA in France (2017–2030)

Figure 28 Total Prevalent Cases of MSA in Italy (2017–2030)

Figure 29 Total Diagnosed Prevalent Cases of MSA in Italy (2017–2030)

Figure 30 Gender-specific Diagnosed Prevalent Cases of MSA in Italy (2017–2030)

Figure 31 Age-specific Diagnosed Prevalent Cases of MSA in Italy (2017–2030)

Figure 32 Type-specific Diagnosed Prevalent Cases of MSA in Italy (2017–2030)

Figure 33 Total Prevalent Cases of MSA in Spain (2017–2030)

Figure 34 Total Diagnosed Prevalent Cases of MSA in Spain (2017–2030)

Figure 35 Gender-specific Diagnosed Prevalent Cases of MSA in Spain (2017–2030)

Figure 36 Age-specific Diagnosed Prevalent Cases of MSA in Spain (2017–2030)

Figure 37 Type-specific Diagnosed Prevalent Cases of MSA in Spain (2017–2030)

Figure 38 Total Prevalent Cases of MSA in the UK (2017–2030)

Figure 39 Total Diagnosed Prevalent Cases of MSA in the UK (2017–2030)

Figure 40 Gender-specific Diagnosed Prevalent Cases of MSA in the UK (2017–2030)

Figure 41 Age-specific Diagnosed Prevalent Cases of MSA in the UK (2017–2030)

Figure 42 Type-specific Diagnosed Prevalent Cases of MSA in the UK (2017–2030)

Figure 43 Total Prevalent Cases of MSA in japan (2017–2030)

Figure 44 Total Diagnosed Prevalent Cases of MSA in Japan (2017–2030)

Figure 45 Gender-specific Diagnosed Prevalent Cases of MSA in Japan (2017–2030)

Figure 46 Age-specific Diagnosed Prevalent Cases of MSA in Japan (2017–2030)

Figure 47 Type-specific Diagnosed Prevalent Cases of MSA in Japan (2017–2030)

  • Tags:
  • Multiple System Atrophy (MSA) Epide...
  • Multiple System Atrophy (MSA)
  • Multiple System Atrophy (MSA) Pipe...
  • Multiple System Atrophy (MSA) Comp...
  • Multiple System Atrophy (MSA) prev...
  • Multiple System Atrophy (MSA) inci...
  • Multiple System Atrophy (MSA) pati...
  • Multiple System Atrophy (MSA) trea...

Forward to Friend

Need A Quote